


## Quick Reference for the Treatment of Acute Agitation

#### Goals of pharmacologic therapy of acute agitation:

- Produce calming effect quickly without excessive sedation
- Provide early treatment of underlying psychosis
- Minimize treatment-related adverse events
- Assure patient and staff safety

# **Options for Management of Acute Agitation with Intramuscular Therapy**



# Should initial treatment fail to produce an adequate response after 2-4 hours (see table opposite side for dosing frequency), options include:

- Give another dose of same medication if partially effective, or a different medication if first medication ineffective
- Give a dose of lorazepam if first medication was an antipsychotic
- Give a combination of the same antipsychotic and lorazepam (except olanzapine)

HLD: haloperidol LRZ: lorazepam OLZ: olanzapine ZIP: Ziprasidone ARP: Aripiprazole *DOC*: drug of choice

**Comparison of IM Treatment Options** 

Medication	Typical Dose	Max Single Dose	Repeat Dosing	Max Adult Dose / 24hrs	Time to Onset (minutes)	Time to Peak Cp (hours)	Half-life (hours)
Lorazepam	1-2mg	4mg	0.5-1 hour	10mg	15	2	13
Haloperidol	5-10mg	10mg	0.5-1 hour	30mg	20-40	1	20
Chlorpromazine *	25-50mg	100mg	1 hour	400m g	15	1-4	6
Ziprasidone**	10mg 20mg	20mg	2 hours 4 hours	40mg	15-30	30-45	2-5
Olanzapine**	10mg	10mg	2-4 hours	30mg	20-60	30	30
Aripiprazole	9.75mg	15mg	2 hours	30mg	45-60	60-180	75

<sup>\*</sup> IM chlorpromazine is not recommended as an option for the management of acute agitation due to significant risk of QTc prolongation and hypotension in doses required for acute agitation, slow onset of effect, and local irritation at the injection site (NICE guidelines)

**Comparison of Oral Agents for Acute Agitation** 

Medication	Typical Dose	Max Singl e Dose	Max Adult Dose/ 24hrs	Time to Onset (minutes)	Time to Peak Cp (hours)	Half-life (hours)				
Lorazepam	1-2mg	4mg	10mg	30-60	2	13				
Haloperidol	5-10mg	10mg	40mg	60-120	2-6	20				
Chlorpromazine	25-50mg	100m g	2000mg	30-60	2.8	30				
Ziprasidone**	20-40mg	40mg	240mg	*	6-8	2-5				
Olanzapine Olanzapine zydis	5-10mg	10mg	30mg	≤ 60	5-8 5-8	30				
Aripiprazole Aripiprazole discmelt	5-10mg 5-10mg	10mg	30mg	*	3-5 3-5	75				
Risperidone Risperidone m-tab Risperidone soln.***	1-2mg 1-2mg 1-2mg	2mg	8mg	* * 60-120	1-2 1-2 1-2	20				

<sup>\*</sup> Not studied as a treatment for acute agitation and aggression

<sup>\*\*</sup>Reconstitution required before administration

<sup>\*\*</sup> The absorption of oral ziprasidone is significantly decreased in the absence of a meal (250-500 calories)

<sup>\*\*\*</sup> When given in combination with IM lorazepam

## **Acute Agitation Clinical Pearls**

- If appropriate, offer oral medication first. This may help the patient restore some feeling of control and ease escalating agitation.
- Rule-out medical complications as a potential cause of agitation (hyperor hypoglycemia, electrolyte disturbance, renal or hepatic failure, thyroid or adrenal disorders, Wernicke's encephalopathy, hypotension, heart failure, neurologic disorders (stroke), meningitis infection (especially in elderly), and dementia).
- Rule-out substance intoxication or withdrawal.
- Rule-out medication causes of acute agitation (steroids, anticholinergics, barbiturates, amphetamines, antipsychotic-induced akathisia).
- Lorazepam is preferred for undifferentiated agitation (provides muscle relaxation, anxiolytic, anticonvulsant effects, and generalized sedation).
- Haloperidol has a relatively low propensity for sedation and hypotension compared with other IM agents; however, it does have a higher incidence of EPS.
- The combination of a benzodiazepine and a typical antipsychotic (i.e., haloperidol) has been shown to be superior to monotherapy with either agent, and may allow for decreased doses of the antipsychotic medication. The combination can cause excessive sedation.
- After treatment with IM agents: monitor vitals and clinical status at regular intervals.
- Allow adequate time for clinical response between doses.
- Use lower starting and maximum doses in the elderly and child and adolescent population.